Abstract
BACKGROUND The interleukin-6 receptor antagonist tocilizumab improves outcomes in critically ill patients with coronavirus disease 2019 (COVID-19). However, the effectiveness of other immune modulating agents is unclear.
METHODS We evaluated four immunomodulatory agents in an ongoing international, multifactorial, adaptive platform trial. Adult participants with COVID-19 were randomized to receive tocilizumab, sarilumab, anakinra, or standard care (control). In addition, a small group (n=21) of participants were randomized to interferon-β1a. The primary outcome was an ordinal scale combining in-hospital mortality (assigned -1) and days free of organ support to day 21. The trial used a Bayesian statistical model with pre-defined triggers for superiority, equivalence or futility.
RESULTS Statistical triggers for equivalence between tocilizumab and sarilumab; and for inferiority of anakinra to the other active interventions were met at a planned adaptive analysis. Of the 2274 critically ill participants enrolled, 972 were assigned to tocilizumab, 485 to sarilumab, 378 to anakinra and 418 to control. Median organ support-free days were 7 (interquartile range [IQR] –1, 16), 9 (IQR –1, 17), 0 (IQR –1, 15) and 0 (IQR –1, 15) for tocilizumab, sarilumab, anakinra and control, respectively. Median adjusted odds ratios were 1.46 (95%CrI 1.13, 1.87), 1.50 (95%CrI 1.13, 2.00), and 0.99 (95%CrI 0.74, 1.35) for tocilizumab, sarilumab and anakinra, yielding 99.8%, 99.8% and 46.6% posterior probabilities of superiority, respectively, compared to control. Median adjusted odds ratios for hospital survival were 1.42 (95%CrI 1.05,1.93), 1.51 (95%CrI 1.06, 2.20) and 0.97 (95%CrI 0.66, 1.40) for tocilizumab, sarilumab and anakinra respectively, compared to control, yielding 98.8%, 98.8% and 43.6% posterior probabilities of superiority, respectively, compared to control. All treatments appeared safe.
CONCLUSIONS In patients with severe COVID-19 receiving organ support, tocilizumab and sarilumab are similarly effective at improving survival and reducing duration of organ support. Anakinra is not effective in this population. (ClinicalTrials.gov number: NCT02735707)
Competing Interest Statement
The Platform for European Preparedness Against (Re-) emerging Epidemics (PREPARE) consortium by the European Union, FP7-HEALTH-2013-INNOVATION-1 (#602525), the Rapid European COVID-19 Emergency Research response (RECOVER) consortium by the European Union Horizon 2020 research and innovation program (#101003589), the Australian National Health and Medical Research Council (#APP1101719), the Health Research Council of New Zealand (#16/631), and the Canadian Institute of Health Research Strategy for Patient-Oriented Research Innovative Clinical Trials Program Grant (#158584), the UK National Institute for Health Research (NIHR) and the NIHR Imperial Biomedical Research Centre, the Health Research Board of Ireland (CTN 2014-012), the UPMC Learning While Doing Program, the Translational Breast Cancer Research Consortium, the Global Coalition for Adaptive Research, the French Ministry of Health (PHRC-20-0147), the Minderoo Foundation, the Wellcome Trust Innovations Project (215522), and the Netherlands Organization for Health Research and Development ZonMw (nr 10150062010003). ACG is funded by an NIHR Research Professorship (RP-2015-06-18) and MSH by an NIHR Clinician Scientist Fellowship (CS-2016-16-011). SYCT is supported by an Australian National Health and Medical Research Council Career Development Fellowship (#APP1145033). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care. Roche Products Ltd, Sanofi (Aventis Pharma Ltd), Swedish Orphan Biovitrum AB (Sobi) and Faron Pharmaceuticals supported the trial through provision of drugs in some countries.
Clinical Trial
ClinicalTrials.gov number: NCT02735707
Clinical Protocols
Funding Statement
The Platform for European Preparedness Against (Re-) emerging Epidemics (PREPARE) consortium by the European Union, FP7-HEALTH-2013-INNOVATION-1 (#602525), the Rapid European COVID-19 Emergency Research response (RECOVER) consortium by the European Union Horizon 2020 research and innovation program (#101003589), the Australian National Health and Medical Research Council (#APP1101719), the Health Research Council of New Zealand (#16/631), and the Canadian Institute of Health Research Strategy for Patient-Oriented Research Innovative Clinical Trials Program Grant (#158584), the UK National Institute for Health Research (NIHR) and the NIHR Imperial Biomedical Research Centre, the Health Research Board of Ireland (CTN 2014-012), the UPMC Learning While Doing Program, the Translational Breast Cancer Research Consortium, the Global Coalition for Adaptive Research, the French Ministry of Health (PHRC-20-0147), the Minderoo Foundation, the Wellcome Trust Innovations Project (215522), and the Netherlands Organization for Health Research and Development ZonMw (nr 10150062010003). ACG is funded by an NIHR Research Professorship (RP-2015-06-18) and MSH by an NIHR Clinician Scientist Fellowship (CS-2016-16-011). SYCT is supported by an Australian National Health and Medical Research Council Career Development Fellowship (#APP1145033). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care. Roche Products Ltd, Sanofi (Aventis Pharma Ltd), Swedish Orphan Biovitrum AB (Sobi) and Faron Pharmaceuticals supported the trial through provision of drugs in some countries.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The trial was approved by the following independent ethics committees in these countries; UK, London-Surrey Borders Research Ethics Committee; Netherlands, Medisch Ethische Toetsingscommissie Utrecht (METC Utrecht); Australia, Sydney Local District ethics Review Committee (Royal Prince Alfred Hospital); New Zealand, Northern A Health and Disability Ethics Committee; Ireland, St Vincent Healthcare Group Ethics and Medical Research Committee; Kingdom of Saudi Arabia, King Abdullah International Medical Research Center Institutional Review Board
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be available to researchers on request subject to sponsor restrictions, please contact cameron.green{at}monash.edu
